X0508 4/A 2024-05-12 2025-05-14 0 0001894525 Apimeds Pharmaceuticals US, Inc. APUS 0002057997 Inscobee Inc. ROOM 613, DIGITAL-RO 130, 6F GEUMCHEON-GU SEOUL M5 08580 KOREA, REPUBLIC OF 0 0 1 0 0 Common Stock, par value $0.0001 per share 4316618 I By Apimeds Inc. The shares of common stock are owned directly by Apimeds Inc. ("Apimeds Korea"), which is a wholly owned subsidiary of the reporting person. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. On May 14, 2025, the reporting person filed a Form 4 (the "Form 4"), which incorrectly reported that the reporting person had indirect beneficial ownership of a Convertible Promissory Note in the amount of $184,833 (the "Note") and the shares of common stock underlying such Note (the "Shares"), through Apimeds Korea. On June 11, 2025, the reporting person filed an amendment to the Form 4 (the "Original Amendment"), to report that the reporting person directly owned the Note and the Shares. The Original Amendment did not update the holdings of Apimeds Korea to reflect that the Note and the Shares were directly owned by the reporting person. This amendment is being filed solely to correct Apimeds Korea's reported holdings. For the avoidance of doubt, as of May 12, 2025, the reporting person had direct beneficial ownership of 2,099,747 shares of common stock and indirect beneficial ownership of 4,316,618 shares of common stock held by Apimeds Korea. /s/ Nelson Mullins Riley & Scarborough LLP, Attorney-in-Fact 2025-11-21